Histone methyltransferase EZH2 in the pathogenesis of lymphoma

VernacularTitle: 组蛋白甲基转移酶EZH2参与淋巴瘤发病机制的研究进展
Author: Lu GAN ¹ ; Hao CHEN ; Jianfang SUN
Author Information

1. Department of Pathology, Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China
Publication Type:Review
Keywords: Methyltransferases; Lymphoma, B-cell; Lymphoma, T-cell; Enhancer of zeste homolog 2
From: Chinese Journal of Dermatology 2020;53(1):71-74
CountryChina
Language:Chinese
Abstract: Epigenetic modification is one of the important causes for the occurrence and development of cancers. Enhancer of zeste homolog 2 (EZH2) , as an important member of the epigenetic suppressor polycomb group (PcG) , can tri-methylate lysine at amino acid position 27 of histone H3 gene, and participates in the regulation of cell cycle, cell aging and cell differentiation. Recently, overexpression or mutation of EZH2 has been detected in a variety of solid tumors and B-cell lymphomas. However, the expression status and action mechanism of EZH2 in some T-cell lymphomas are still unclear, and its action mechanisms in different tumors are not completely consistent, which need further study.